Survival time is generally poor for malignant gliomas, such as glioblastoma, with 95% of untreated patients surviving no more than 3 months. Patient prognosis is multifactorial; patients who are under 45 years of age, have preoperative symptoms for more than 6 months, have predominantly epileptic rather than psychiatric disorders, have tumors located in the frontal lobe, and are in good preoperative condition have a slightly longer survival time. The degree of tumor resection affects patient survival; 6-month and 2-year survival after partial resection or tumor biopsy is half that of patients with total resection of the sarcomere tumor, and total sarcomere tumor resection is helpful in improving patients’ neurological symptoms. Radiotherapy prolongs survival by 4-9 months, and postoperative radiotherapy allows some patients to survive up to 18 months. However, although combination therapy for glioblastoma may temporarily relieve progression, it does not cure the tumor. With a combination of treatments, 2-year survival is 10%, and less than 5% of patients survive long term, such as in gliosarcoma, where the prognosis is even worse, with an average survival of only 4-8 months after surgery.